Dr. Knesevich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4600 Samuell Blvd
Dallas, TX 75228Phone+1 214-381-7181
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Psychiatry, 1982 - 1986- Washington University/B-JH/SLCH ConsortiumInternship, Transitional Year, 1981 - 1982
Indiana University School of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1990 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) Start of enrollment: 2016 Oct 29
- ERG Components in Schizophrenia and Bipolar Disorder Type I Start of enrollment: 2018 Jul 05
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 159 citationsKINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaRobert A. Hauser, Stewart A. Factor, Stephen R. Marder, Mary Ann Knesevich, Paul Michael Ramirez
The American Journal of Psychiatry. 2017-03-21 - 40 citationsAdjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Robert Lasser, Bryan Dirks, Henry Nasrallah, Courtney Kirsch, Joseph Gao
Neuropsychopharmacology. 2013-05-08 - 30 citationsGenetic and State Variables of Neurocognitive Dysfunction in Schizophrenia: A Twin StudyPatricia J. Pardo, Mary Ann Knesevich, George P. Vogler, José V. Pardo, Bradford Towne
Schizophrenia Bulletin. 2000-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
